SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cosmo Daisey who wrote (644)5/5/1998 9:58:00 AM
From: Graham Dellaire  Read Replies (2) of 2135
 
Cosmo when this data first came out LAST YEAR, I asked around at the cancer intitute I work at. The consensus was even in human tumor implantation models weird things go on in the mouse. One treatement can work amazingly and then have almost no effect in man.

Caution. But I feel endostatin and angiostatin may be different. THe fact they seem to have no side-effects and do not lead to drug resistance is very, very promising in any case.

I repeat the stock is way ahead of itself. If you bought in the teens or lower sell, return when the stock hits the mid to low 20's.

My opnion. But I was also into this stock last year at 10.5.

Graham
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News